Separately, Roth Capital started coverage on Neuralstem in a research report on Monday, August 29th. They set a buy rating and a $1.20 price objective on the stock.
Shares of Neuralstem (NASDAQ:CUR) traded down 0.3765% during midday trading on Tuesday, reaching $0.3175. The company’s stock had a trading volume of 28,901 shares. Neuralstem has a 12-month low of $0.19 and a 12-month high of $1.35. The company’s 50-day moving average price is $0.29 and its 200 day moving average price is $0.38. The company’s market capitalization is $36.44 million.
Neuralstem (NASDAQ:CUR) last announced its quarterly earnings data on Thursday, August 11th. The company reported ($0.04) EPS for the quarter, beating the consensus estimate of ($0.05) by $0.01. The firm had revenue of $2.50 million for the quarter, compared to analyst estimates of $2.50 million. Neuralstem had a negative return on equity of 574.32% and a negative net margin of 173,849.97%. On average, equities research analysts forecast that Neuralstem will post ($0.17) earnings per share for the current year.
Institutional investors have recently made changes to their positions in the stock. Sabby Management LLC purchased a new position in shares of Neuralstem during the second quarter valued at approximately $1,893,000. Vanguard Group Inc. boosted its stake in shares of Neuralstem by 21.8% in the second quarter. Vanguard Group Inc. now owns 3,384,138 shares of the company’s stock valued at $984,000 after buying an additional 606,500 shares in the last quarter. Finally, Blair William & Co. IL bought a new stake in shares of Neuralstem during the second quarter valued at $122,000. Hedge funds and other institutional investors own 18.20% of the company’s stock.
Neuralstem, Inc (Neuralstem) is a clinical-stage biopharmaceutical company. The Company is engaged in research, development and commercialization of central nervous system therapies based on its human neuronal stem cells and its stem-cell derived small molecule compounds. The Company has approximately three assets: its NSI-189 small molecule program, its NSI-566 stem cell therapy program and its chemical entity screening platform.
Receive News & Ratings for Neuralstem Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neuralstem Inc. and related companies with MarketBeat.com's FREE daily email newsletter.